By hijacking Fbln1/FAK signaling, DAO not only rewires muscle energy metabolism but also erodes the mechanical infrastructure essential for force production—a dual assault that underscores its potential as a therapeutic target for sarcopenia and related myopathies. The gene discussed is PTK2; the disease is sarcopenia.